Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17082946 | 0.86 | POLB (0.48) | POLBMAPTALDH1A1GLAAR | |
| SCHEMBL660327 | 0.85 | ADRB1 (0.43) | POLBMAPTALDH1A1GLAOPRM1 | |
| SCHEMBL659504 | 0.84 | BDKRB2 (0.46) | POLBMAPTALDH1A1ARSLC6A9 | |
| SCHEMBL17082982 | 0.84 | POLB (0.45) | POLBMAPTALDH1A1GLAAR | |
| SCHEMBL421867 | 0.83 | AKR1B1 (0.37) | POLBMAPTALDH1A1GLASMN1; SMN2 | |
| SCHEMBL17077228 | 0.83 | MAPT (0.45) | MAPTALDH1A1ARSLC6A9OPRM1 | |
| SCHEMBL18961831 | 0.83 | LMNA (0.46) | MAPTSMN1; SMN2SLC6A9OPRM1 | |
| SCHEMBL190640 | 0.83 | ALDH1A1 (0.55) | POLBMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL2544529 | 0.81 | MMP13 (0.46) | MAPTSMN1; SMN2SLC6A9OPRM1 | |
| SCHEMBL17082985 | 0.81 | AR (0.44) | POLBMAPTALDH1A1GLAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944607-B2 | Thiohydantoin derivatives and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944607-B2 | Thiohydantoin derivatives and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-17 | — | — | US | disclosed |
| US-20150259298-A1 | THIOHYDANTOIN DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259298-A1 | THIOHYDANTOIN DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-09-17 | — | — | US | disclosed |
| US-8420681-B2 | Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120021016-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2401260-A1 | DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097465-A1 | DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259298-A1 | THIOHYDANTOIN DERIVATIVES AND USES THEREOF | TPI1, SLC25A1, HOGA1 | POLB 2884/4885MAPT 389/4885ALDH1A1 2008/4885 |
| US-20120021016-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | SOAT1, SOAT2, ODC1 | POLB 887/4885MAPT 2865/4885ALDH1A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.